Equilibrium Dialysis and Ultrafiltration Compared for Determining the Protein Binding Rates of 99mTc-DTPA
Keywords:
99mTc-DTPA, Protein Binding, Human Serum, Human Serum Albumin, Equilibrium Dialysis, Ultrafiltration.Abstract
Diethylene triaminopentaacetic acid (99mTc-DTPA) is one of the technetium radiopharmaceuticals mostly used in renal imaging for evaluation of glomera filtration rate. The 99mTc-DTPA binding rates on plasma proteins was investigated using two useful and reproducible methods. Equilibrium Dialysis (ED) and Ultrafiltration (UF) are described and there are performances compared. 99mTc-DTPA binds strongly to Human Serum (HS) than to Human Serum Albumin (HSA). In our assay, using UF technique, we found the binding rates were in HS 48.72 % ±2.58 and 51 % ±1.43 for respectively two 99mTc-DTPA concentrations [1mg/L] and [2mg/L]. Using ED method we found the binding rates were in HS 11.22 % ±2.17 and 14.94 % ±2.30 for respectively two 99m Tc-DTPA concentrations [1mg/L] and [2mg/L]. Moreover, According to HSA concentrations, the 99m Tc-DTPA binding rates increase using both techniques.
References
[1] M. Abbas, L. Ahmad, Y. Shah, M. Gill, and D. G. Watson, ‘Development of a method to measure free and bound ropivacaine in human plasma using equilibrium dialysis and Hydrophilic interaction chromatography coupled to high resolution mass spectrometry’, Talanta, vol. 117, pp. 60–63, Dec. 2013.
[2] Y. Tang, H. Zhu, Y. Zhang, and C. Huang, ‘Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography’, Biomed. Chromatogr., vol. 20, no. 10, pp. 1116–1119, Oct. 2006.
[3] A. Dasgupta, ‘Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management’, Clin. Chim. Acta, vol. 377, no. 1–2, pp. 1–13, Feb. 2007.
[4] S. Vallabhajosula, R. P. Killeen, and J. R. Osborne, ‘Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors’, Seminars in nuclear medicine, pp. 220–241, 2010.
[5] F. J. Klocke, ‘ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)’, Circulation, vol. 108, no. 11, pp. 1404–1418, Sep. 2003.
[6] M. A. L. Eriksson, J. Gabrielsson, and L. B. Nilsson, ‘Studies of drug binding to plasma proteins using a variant of equilibrium dialysis’, J. Pharm. Biomed. Anal., vol. 38, no. 3, pp. 381–389, Jul. 2005.
[7] H. Wan and M. Rehngren, ‘High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry’, J. Chromatogr. A, vol. 1102, no. 1–2, pp. 125–134, Jan. 2006.
[8] J.W. Hilson, B. Chir, R.D. Mistry, and N.M. Maisey, ‘99mTc for the measurement of glomerular filtration rate’, British Journal of Radiology, pp. 794–796, 1976.
[9] C. Maioli, A. Bestetti, F. Milani , G.P. Cornalba, L. Tagliabue, D.D. Benedetto et al., ‘Evaluation of different counting methods for use in radiochemical purity testing procedures for 99mTc-labelled radiopharmaceuticals’, Appl. Radiat. Isot., vol. 66, no. 4, pp. 556–559, Apr. 2008.
[10] ‘European Pharmacopoeia Ed 7 2011’. .
[11] C. .Hojelse, K. Kristensen, C.B. Sampson, ‘Factors which affectthe integrity of radiopharmaceuticals’, in Textbook of radiopharmacy, theory and practice, Gordon and Breach Science Publishers., Amsterdam: Sampson CB, editor, 1994, pp. 145–152.
[12] N. Vanli?-Razumeni?, J. Joksimovi?, B. Risti?, M. Tomi?, S. Beatov?, and B. Ajdinovi?, ‘Interaction of 99mTc-radiopharmaceuticals with transport proteins in human blood’, Nucl. Med. Biol., vol. 20, no. 3, pp. 363–365, 1993.
[13] A. E.B. Moore, S. F. Hain, G. M. Blake, and I. Fogelman, ‘Validation of Ultrafiltration as a Method of Measuring Free 99mTc-MDP’, J Nucl Med, pp. 891–897, 2003.
[14] M. Rehling, L.E. Nielsen and J. Marqversen, ‘Protein binding of 99mTc-DTPA compared with other GFR tracers’, Nuclear Medicine Communications, pp. 617–623, 2001.
[15] K.L Lee, R. Mower, T. Hollenbeck, J. Castelo, N. Johnson, P. Gordon et al., ‘Modulation of nonspecific binding in ultrafiltration protein binding studies’, Pharm. Res., vol. 20, no. 7, pp. 1015–1021, 2003.
[16] R. Ghosh and Z. F. Cui, ‘Fractionation of BSA and lysozyme using ultrafiltration: effect of pH and membrane pretreatment’, J. Membr. Sci., vol. 139, no. 1, pp. 17–28, 1998.
[17] Y. M. Huigen, T. G. Tji, W. J. Gelsema and C. L. de Ligny, ‘The Binding of 99mTc(Sn)-MDP Complexes to Human Serum Albumin and Other Blood Proteins Determined with Gel Chromatography and Ultrafiltration’, Appl. Radiat. lsot, pp. 629–635, 1989.
[18] B. Sebille, ‘Separation procedures used to reveal and follow drug-protein binding’, Journal of Chromatography, B: Biomedical Applications, pp. 51–77, 1990.
[19] M. Qiao, X. Guo, and F. Li, ‘Chemiluminescence detection coupled to high-performance frontal analysis for the determination of unbound concentrations of drugs in protein binding equilibrium’, J. Chromatogr. A, vol. 952, no. 1–2, pp. 131–138, 2002.
[20] C. Y. Lui and W. L. Chiou, ‘pH Shift during equilibrium dialysis’, Biopharm. Drug Dispos., vol. 7, no. 3, pp. 309–314, 1986.
[21] T. Trtic´-Petrovic, J.F Liu, J.A Jonsson, ‘Equilibrium sampling through membrane based on a single hollow fibre for determination of drug–protein binding and free drug concentration in plasma’, Journal of Chromatography B, pp. 169–176, 2005.
[22] J. Barré, J. M. Chamouard, G. Houin and J.P. Tlllement, ‘Equilibrium Dialysis, Ultrafiltration, and Ultracentrifugation Compared for Determining the Plasma-Protein-Binding Characteristics of ValproicAcid’, CLIN. CHEM., pp. 60–64, 1985.
[2] Y. Tang, H. Zhu, Y. Zhang, and C. Huang, ‘Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography’, Biomed. Chromatogr., vol. 20, no. 10, pp. 1116–1119, Oct. 2006.
[3] A. Dasgupta, ‘Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management’, Clin. Chim. Acta, vol. 377, no. 1–2, pp. 1–13, Feb. 2007.
[4] S. Vallabhajosula, R. P. Killeen, and J. R. Osborne, ‘Altered biodistribution of radiopharmaceuticals: role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors’, Seminars in nuclear medicine, pp. 220–241, 2010.
[5] F. J. Klocke, ‘ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging)’, Circulation, vol. 108, no. 11, pp. 1404–1418, Sep. 2003.
[6] M. A. L. Eriksson, J. Gabrielsson, and L. B. Nilsson, ‘Studies of drug binding to plasma proteins using a variant of equilibrium dialysis’, J. Pharm. Biomed. Anal., vol. 38, no. 3, pp. 381–389, Jul. 2005.
[7] H. Wan and M. Rehngren, ‘High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry’, J. Chromatogr. A, vol. 1102, no. 1–2, pp. 125–134, Jan. 2006.
[8] J.W. Hilson, B. Chir, R.D. Mistry, and N.M. Maisey, ‘99mTc for the measurement of glomerular filtration rate’, British Journal of Radiology, pp. 794–796, 1976.
[9] C. Maioli, A. Bestetti, F. Milani , G.P. Cornalba, L. Tagliabue, D.D. Benedetto et al., ‘Evaluation of different counting methods for use in radiochemical purity testing procedures for 99mTc-labelled radiopharmaceuticals’, Appl. Radiat. Isot., vol. 66, no. 4, pp. 556–559, Apr. 2008.
[10] ‘European Pharmacopoeia Ed 7 2011’. .
[11] C. .Hojelse, K. Kristensen, C.B. Sampson, ‘Factors which affectthe integrity of radiopharmaceuticals’, in Textbook of radiopharmacy, theory and practice, Gordon and Breach Science Publishers., Amsterdam: Sampson CB, editor, 1994, pp. 145–152.
[12] N. Vanli?-Razumeni?, J. Joksimovi?, B. Risti?, M. Tomi?, S. Beatov?, and B. Ajdinovi?, ‘Interaction of 99mTc-radiopharmaceuticals with transport proteins in human blood’, Nucl. Med. Biol., vol. 20, no. 3, pp. 363–365, 1993.
[13] A. E.B. Moore, S. F. Hain, G. M. Blake, and I. Fogelman, ‘Validation of Ultrafiltration as a Method of Measuring Free 99mTc-MDP’, J Nucl Med, pp. 891–897, 2003.
[14] M. Rehling, L.E. Nielsen and J. Marqversen, ‘Protein binding of 99mTc-DTPA compared with other GFR tracers’, Nuclear Medicine Communications, pp. 617–623, 2001.
[15] K.L Lee, R. Mower, T. Hollenbeck, J. Castelo, N. Johnson, P. Gordon et al., ‘Modulation of nonspecific binding in ultrafiltration protein binding studies’, Pharm. Res., vol. 20, no. 7, pp. 1015–1021, 2003.
[16] R. Ghosh and Z. F. Cui, ‘Fractionation of BSA and lysozyme using ultrafiltration: effect of pH and membrane pretreatment’, J. Membr. Sci., vol. 139, no. 1, pp. 17–28, 1998.
[17] Y. M. Huigen, T. G. Tji, W. J. Gelsema and C. L. de Ligny, ‘The Binding of 99mTc(Sn)-MDP Complexes to Human Serum Albumin and Other Blood Proteins Determined with Gel Chromatography and Ultrafiltration’, Appl. Radiat. lsot, pp. 629–635, 1989.
[18] B. Sebille, ‘Separation procedures used to reveal and follow drug-protein binding’, Journal of Chromatography, B: Biomedical Applications, pp. 51–77, 1990.
[19] M. Qiao, X. Guo, and F. Li, ‘Chemiluminescence detection coupled to high-performance frontal analysis for the determination of unbound concentrations of drugs in protein binding equilibrium’, J. Chromatogr. A, vol. 952, no. 1–2, pp. 131–138, 2002.
[20] C. Y. Lui and W. L. Chiou, ‘pH Shift during equilibrium dialysis’, Biopharm. Drug Dispos., vol. 7, no. 3, pp. 309–314, 1986.
[21] T. Trtic´-Petrovic, J.F Liu, J.A Jonsson, ‘Equilibrium sampling through membrane based on a single hollow fibre for determination of drug–protein binding and free drug concentration in plasma’, Journal of Chromatography B, pp. 169–176, 2005.
[22] J. Barré, J. M. Chamouard, G. Houin and J.P. Tlllement, ‘Equilibrium Dialysis, Ultrafiltration, and Ultracentrifugation Compared for Determining the Plasma-Protein-Binding Characteristics of ValproicAcid’, CLIN. CHEM., pp. 60–64, 1985.
Downloads
Published
2018-11-14
How to Cite
Chemlal, L., Makram, S., Aoullay, Z., Doudach, L., Zoubir, B., Cherrah, Y., & Faouzi, M. A. (2018). Equilibrium Dialysis and Ultrafiltration Compared for Determining the Protein Binding Rates of 99mTc-DTPA. American Scientific Research Journal for Engineering, Technology, and Sciences, 49(1), 19–27. Retrieved from https://www.asrjetsjournal.org/index.php/American_Scientific_Journal/article/view/4468
Issue
Section
Articles
License
Authors who submit papers with this journal agree to the following terms.
